Invention Grant
- Patent Title: Pharmaceutical compositions for treatment of HCV patients that are poor-responders to interferon
- Patent Title (中): 用于治疗干扰素反应不良的HCV患者的药物组合物
-
Application No.: US12767631Application Date: 2010-04-26
-
Publication No.: US09034837B2Publication Date: 2015-05-19
- Inventor: Elisabeth S. Hildebrandt-Eriksen , Andreas Petri , Sakari Kauppinen , Niels Abrahamsen , Robert Eldon Lanford
- Applicant: Elisabeth S. Hildebrandt-Eriksen , Andreas Petri , Sakari Kauppinen , Niels Abrahamsen , Robert Eldon Lanford
- Applicant Address: DE Hørsholm
- Assignee: Roche Innovation Center Copenhagen A/S
- Current Assignee: Roche Innovation Center Copenhagen A/S
- Current Assignee Address: DE Hørsholm
- Agency: Sterne, Kessler, Goldstein & Fox P.L.L.C.
- Main IPC: A61K48/00
- IPC: A61K48/00 ; C07H21/02 ; C07H21/04 ; A61K31/7105 ; C12N15/113
Abstract:
The present invention provides compositions and methods of treatment of HCV infected subjects that are not sensitive to interferon treatment. Further, compositions and methods are provided for prevention of organ transplant rejection. The compositions of the invention comprise an anti microRNA-122 oligonucleotide, and are made for administration to a primate.
Public/Granted literature
- US20100330035A1 Pharmaceutical Compositions for Treatment of HCV Patients that are Poor-Responders to Interferon Public/Granted day:2010-12-30
Information query
